Literature DB >> 19559412

Clinical assessment of fracture risk and novel therapeutic strategies to combat osteoporosis.

Mark S Nanes1, Caleb B Kallen.   

Abstract

OBJECTIVE: To review the latest tools in the clinical assessment of fracture risk and to review new and emerging options for osteoporosis therapy.
DESIGN: Retrospective analysis of published studies regarding the diagnosis and treatment of osteoporosis. RESULT(S): Large-scale epidemiologic data were recently assembled by the World Health Organization to produce a Web-based clinical assessment tool, FRAX, which uses clinical and historical data to provide prompt assessment and quantitation of fracture risk. The FRAX models were developed from studying population-based cohorts in Europe, North America, Asia, and Australia. The FRAX algorithms indicate the 10-year probability of hip fracture and the 10-year probability of a major osteoporotic fracture (at the clinical spine, forearm, hip, or shoulder) on which to base treatment decisions. Recent progress in the study of bone metabolism including anabolic pathways that enhance bone maintenance, is anticipated to improve the ways in which skeletal health can be maintained and osteoporosis can be treated. CONCLUSION(S): Using FRAX, fracture risk in now easily assessed in the clinical setting. New and emerging treatment strategies for bone maintenance are reviewed. Improved assessment of fracture risk, combined with tailored therapies for at-risk patients, will increase the number of patients who receive appropriate bone-sparing therapies.

Entities:  

Mesh:

Year:  2009        PMID: 19559412     DOI: 10.1016/j.fertnstert.2009.05.049

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  5 in total

Review 1.  Current, new and future treatments of osteoporosis.

Authors:  Pooneh Salari Sharif; Mohammad Abdollahi; Bagher Larijani
Journal:  Rheumatol Int       Date:  2010-07-30       Impact factor: 2.631

2.  Ethanol Extract of Cissus quadrangularis Enhances Osteoblast Differentiation and Mineralization of Murine Pre-Osteoblastic MC3T3-E1 Cells.

Authors:  Raazia Tasadduq; Jonathan Gordon; Khalid A Al-Ghanim; Jane B Lian; Andre J Van Wijnen; Janet L Stein; Gary S Stein; Abdul Rauf Shakoori
Journal:  J Cell Physiol       Date:  2016-06-15       Impact factor: 6.384

3.  The utility and limitations of FRAX: A US perspective.

Authors:  Stuart L Silverman; Andrew D Calderon
Journal:  Curr Osteoporos Rep       Date:  2010-12       Impact factor: 5.096

4.  Genetic factors influencing bone mineral content in a black South African population.

Authors:  Andrew May; John M Pettifor; Shane A Norris; Michèle Ramsay; Zané Lombard
Journal:  J Bone Miner Metab       Date:  2013-03-09       Impact factor: 2.626

5.  Live imaging of osteoclast inhibition by bisphosphonates in a medaka osteoporosis model.

Authors:  Tingsheng Yu; Paul Eckhard Witten; Ann Huysseune; Anita Buettner; Thuy Thanh To; Christoph Winkler
Journal:  Dis Model Mech       Date:  2015-12-24       Impact factor: 5.758

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.